We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Innophos (IPHS) Earnings Miss Estimates in Q3, Sales Rise Y/Y
Read MoreHide Full Article
Innophos Holdings, Inc. posted a profit of $14 million or 71 cents per share in third-quarter 2018, up from a profit of $11 million or 58 cents a year.
Barring one-time items, the company’s adjusted earnings per share (EPS) were 58 cents per share in the quarter, which trailed the Zacks Consensus Estimate of 64 cents.
Net sales totaled $197 million in the reported quarter, up around 7% year over year on contribution from acquisitions, a stabilized base portfolio and pricing actions.
Innophos Holdings, Inc. Price, Consensus and EPS Surprise
Revenues at the FHN segment climbed 17% year over year to $115 million in the third quarter, driven by contribution from acquisitions.
The Industrial Specialties (IS) division recorded revenues of $66 million in the quarter, down 3% year over year. Volumes were down 9%, offset by increase in selling price that rose 6%.
Other sales fell 10% year over year to $16 million on lower co-product sales.
Financials
Innophos ended the quarter with cash and cash equivalents of $23 million, down 29.4% year over year. Long-term debt was $345 million, up 17% year over year. Net cash provided by operating activities for the first nine months of 2018 was $30.8 million, a roughly 34% year-over-year decline.
Outlook
Innophos expects year-over-year revenue growth of 10-12% in 2018 which equates to a range of $791-$806 million.
The company envisions adjusted EBITDA growth of 3-7% year over year, which equates to a range of $123-$128 million. Earnings in 2018 are likely to be affected by strategic value chain repositioning transition costs. In the fourth quarter, the company expects seasonality to impact sales. Moreover, the company anticipates effective tax rate to operate in the range of 29-31%.
Innophos’ fourth-quarter free cash flow is expected to benefit from its earlier announced plans to complete a sale leaseback transaction and Nutrien contractual payment of $20 million.
By the end of 2019, the company’s multi-faceted value chain repositioning and manufacturing optimization program are forecast to deliver adjusted EPS improvement of 10%, representing an estimated run rate of 25-27 cents a share.
Price Performance
Innophos’ shares are down 32.5% in a year, underperforming the loss of 15.4% recorded by the industry.
Zacks Rank and Stocks to Consider
Innophos currently carries a Zacks Rank #5 (Strong Sell).
A few better-ranked stocks in the basic materials space are CF Industries Holdings, Inc. (CF - Free Report) , KMG Chemicals, Inc. and The Mosaic Company (MOS - Free Report) .
CF Industries has an expected long-term earnings growth rate of 6% and a Zacks Rank #1 (Strong Buy). The company’s shares have gained 26.7% in the past year. You can see the complete list of today’s Zacks #1 Rank stocks here.
KMG Chemicals has an expected long-term earnings growth rate of 28.5% and a Zacks Rank #2 (Buy). Its shares have risen 43.2% in a year’s time.
Mosaic has an expected long-term earnings growth rate of 7% and a Zacks Rank #2. The company’s shares have rallied 41.9% in the past year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Innophos (IPHS) Earnings Miss Estimates in Q3, Sales Rise Y/Y
Innophos Holdings, Inc. posted a profit of $14 million or 71 cents per share in third-quarter 2018, up from a profit of $11 million or 58 cents a year.
Barring one-time items, the company’s adjusted earnings per share (EPS) were 58 cents per share in the quarter, which trailed the Zacks Consensus Estimate of 64 cents.
Net sales totaled $197 million in the reported quarter, up around 7% year over year on contribution from acquisitions, a stabilized base portfolio and pricing actions.
Innophos Holdings, Inc. Price, Consensus and EPS Surprise
Innophos Holdings, Inc. Price, Consensus and EPS Surprise | Innophos Holdings, Inc. Quote
Segment Highlights
Revenues at the FHN segment climbed 17% year over year to $115 million in the third quarter, driven by contribution from acquisitions.
The Industrial Specialties (IS) division recorded revenues of $66 million in the quarter, down 3% year over year. Volumes were down 9%, offset by increase in selling price that rose 6%.
Other sales fell 10% year over year to $16 million on lower co-product sales.
Financials
Innophos ended the quarter with cash and cash equivalents of $23 million, down 29.4% year over year. Long-term debt was $345 million, up 17% year over year. Net cash provided by operating activities for the first nine months of 2018 was $30.8 million, a roughly 34% year-over-year decline.
Outlook
Innophos expects year-over-year revenue growth of 10-12% in 2018 which equates to a range of $791-$806 million.
The company envisions adjusted EBITDA growth of 3-7% year over year, which equates to a range of $123-$128 million. Earnings in 2018 are likely to be affected by strategic value chain repositioning transition costs. In the fourth quarter, the company expects seasonality to impact sales. Moreover, the company anticipates effective tax rate to operate in the range of 29-31%.
Innophos’ fourth-quarter free cash flow is expected to benefit from its earlier announced plans to complete a sale leaseback transaction and Nutrien contractual payment of $20 million.
By the end of 2019, the company’s multi-faceted value chain repositioning and manufacturing optimization program are forecast to deliver adjusted EPS improvement of 10%, representing an estimated run rate of 25-27 cents a share.
Price Performance
Innophos’ shares are down 32.5% in a year, underperforming the loss of 15.4% recorded by the industry.
Zacks Rank and Stocks to Consider
Innophos currently carries a Zacks Rank #5 (Strong Sell).
A few better-ranked stocks in the basic materials space are CF Industries Holdings, Inc. (CF - Free Report) , KMG Chemicals, Inc. and The Mosaic Company (MOS - Free Report) .
CF Industries has an expected long-term earnings growth rate of 6% and a Zacks Rank #1 (Strong Buy). The company’s shares have gained 26.7% in the past year. You can see the complete list of today’s Zacks #1 Rank stocks here.
KMG Chemicals has an expected long-term earnings growth rate of 28.5% and a Zacks Rank #2 (Buy). Its shares have risen 43.2% in a year’s time.
Mosaic has an expected long-term earnings growth rate of 7% and a Zacks Rank #2. The company’s shares have rallied 41.9% in the past year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>